{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,11]],"date-time":"2026-10-11T13:45:30Z","timestamp":1791726330600,"version":"4.3.4"},"reference-count":215,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,6,1]],"date-time":"2023-06-01T00:00:00Z","timestamp":1685577600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,3,24]],"date-time":"2023-03-24T00:00:00Z","timestamp":1679616000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"funder":[{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20200201367JC"],"award-info":[{"award-number":["20200201367JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20200201473JC"],"award-info":[{"award-number":["20200201473JC"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20210204165YY"],"award-info":[{"award-number":["20210204165YY"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007847","name":"Natural Science Foundation of Jilin Province","doi-asserted-by":"publisher","award":["20210401057YY"],"award-info":[{"award-number":["20210401057YY"]}],"id":[{"id":"10.13039\/100007847","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81802815"],"award-info":[{"award-number":["81802815"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81972558"],"award-info":[{"award-number":["81972558"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","em-consulte.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Biomedicine & Pharmacotherapy"],"published-print":{"date-parts":[[2023,6]]},"DOI":"10.1016\/j.biopha.2023.114609","type":"journal-article","created":{"date-parts":[[2023,3,28]],"date-time":"2023-03-28T23:11:24Z","timestamp":1680045084000},"page":"114609","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":16,"special_numbering":"C","title":["Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer"],"prefix":"10.1016","volume":"162","author":[{"given":"Qingjie","family":"He","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haibo","family":"Hu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dong","family":"Song","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaoling","family":"Zhang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiangpeng","family":"Dai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib1","first-page":"209","article-title":"Global Cancer Statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"71","author":"Sung","year":"2021","journal-title":"CA Cancer J. Clin."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib2","doi-asserted-by":"crossref","first-page":"678","DOI":"10.1038\/s41591-022-01765-8","article-title":"Engineered cellular immunotherapies in cancer and beyond","volume":"28","author":"Finck","year":"2022","journal-title":"Nat. Med"},{"issue":"8","key":"10.1016\/j.biopha.2023.114609_bib3","doi-asserted-by":"crossref","first-page":"417","DOI":"10.1038\/s41568-020-0266-x","article-title":"Key steps for effective breast cancer prevention","volume":"20","author":"Britt","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"10286","key":"10.1016\/j.biopha.2023.114609_bib4","doi-asserted-by":"crossref","first-page":"1750","DOI":"10.1016\/S0140-6736(20)32381-3","article-title":"Breast cancer","volume":"397","author":"Loibl","year":"2021","journal-title":"Lancet"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib5","doi-asserted-by":"crossref","first-page":"66","DOI":"10.1038\/s41572-019-0111-2","article-title":"Breast cancer","volume":"5","author":"Harbeck","year":"2019","journal-title":"Nat. Rev. Dis. Prim."},{"key":"10.1016\/j.biopha.2023.114609_bib6","doi-asserted-by":"crossref","first-page":"114","DOI":"10.1016\/j.semcancer.2020.03.002","article-title":"Current and potential immunohistochemical biomarkers for prognosis and therapeutic stratification of breast carcinoma","volume":"72","author":"Ronchi","year":"2021","journal-title":"Semin Cancer Biol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib7","doi-asserted-by":"crossref","first-page":"288","DOI":"10.1001\/jama.2018.19323","article-title":"Breast cancer treatment: a review","volume":"321","author":"Waks","year":"2019","journal-title":"JAMA"},{"key":"10.1016\/j.biopha.2023.114609_bib8","article-title":"The landscape of chimeric antigen receptor T cell therapy in breast cancer: Perspectives and outlook","volume":"13","author":"Zhang","year":"2022","journal-title":"Front Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib9","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","article-title":"Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia","volume":"378","author":"Park","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"27","key":"10.1016\/j.biopha.2023.114609_bib10","doi-asserted-by":"crossref","first-page":"3044","DOI":"10.1200\/JCO.20.03458","article-title":"Humanized CD19-Targeted Chimeric Antigen Receptor (CAR) T Cells in CAR-Naive and CAR-Exposed Children and Young Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia","volume":"39","author":"Myers","year":"2021","journal-title":"J. Clin. Oncol."},{"issue":"26","key":"10.1016\/j.biopha.2023.114609_bib11","doi-asserted-by":"crossref","first-page":"2531","DOI":"10.1056\/NEJMoa1707447","article-title":"Axicabtagene Ciloleucel CAR T-Cell Therapy in Refractory Large B-Cell Lymphoma","volume":"377","author":"Neelapu","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"26","key":"10.1016\/j.biopha.2023.114609_bib12","doi-asserted-by":"crossref","first-page":"2545","DOI":"10.1056\/NEJMoa1708566","article-title":"Chimeric antigen receptor T cells in refractory B-cell lymphomas","volume":"377","author":"Schuster","year":"2017","journal-title":"N. Engl. J. Med"},{"issue":"14","key":"10.1016\/j.biopha.2023.114609_bib13","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","article-title":"KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma","volume":"382","author":"Wang","year":"2020","journal-title":"N. Engl. J. Med"},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib14","doi-asserted-by":"crossref","first-page":"673","DOI":"10.1056\/NEJMc2030164","article-title":"P. Lymphoma Program Investigators at the University of, Five-Year Outcomes for Refractory B-Cell Lymphomas with CAR T-Cell Therapy","volume":"384","author":"Chong","year":"2021","journal-title":"N. Engl. J. Med"},{"issue":"18","key":"10.1016\/j.biopha.2023.114609_bib15","doi-asserted-by":"crossref","first-page":"1726","DOI":"10.1056\/NEJMoa1817226","article-title":"Anti-BCMA CAR T-Cell Therapy bb2121 in Relapsed or Refractory Multiple Myeloma","volume":"380","author":"Raje","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib16","doi-asserted-by":"crossref","first-page":"1129","DOI":"10.1016\/j.apsb.2020.10.020","article-title":"CAR-T cells: Early successes in blood cancer and challenges in solid tumors","volume":"11","author":"Dana","year":"2021","journal-title":"Acta Pharm. Sin. B"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib17","doi-asserted-by":"crossref","first-page":"166","DOI":"10.1038\/s41392-020-00280-x","article-title":"The updated landscape of tumor microenvironment and drug repurposing","volume":"5","author":"Jin","year":"2020","journal-title":"Signal Transduct. Target Ther."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib18","doi-asserted-by":"crossref","first-page":"107","DOI":"10.1111\/imr.12131","article-title":"Design and development of therapies using chimeric antigen receptor-expressing T cells","volume":"257","author":"Dotti","year":"2014","journal-title":"Immunol. Rev."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib19","doi-asserted-by":"crossref","first-page":"86","DOI":"10.1186\/s13045-020-00910-5","article-title":"Recent advances in CAR-T cell engineering","volume":"13","author":"Huang","year":"2020","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib20","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1038\/s41416-018-0325-1","article-title":"S. Kobold, Teaching an old dog new tricks: next-generation CAR T cells","volume":"120","author":"Tokarew","year":"2019","journal-title":"Br. J. Cancer"},{"issue":"20 Pt 1","key":"10.1016\/j.biopha.2023.114609_bib21","doi-asserted-by":"crossref","first-page":"6106","DOI":"10.1158\/1078-0432.CCR-06-1183","article-title":"A phase I study on adoptive immunotherapy using gene-modified T cells for ovarian cancer","volume":"12","author":"Kershaw","year":"2006","journal-title":"Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib22","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1158\/2159-8290.CD-12-0548","article-title":"The basic principles of chimeric antigen receptor design","volume":"3","author":"Sadelain","year":"2013","journal-title":"Cancer Disco"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib23","doi-asserted-by":"crossref","first-page":"282","DOI":"10.1038\/s41419-018-0278-6","article-title":"CAR-T cells: the long and winding road to solid tumors","volume":"9","author":"D'Aloia","year":"2018","journal-title":"Cell Death Dis."},{"key":"10.1016\/j.biopha.2023.114609_bib24","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1146\/annurev-immunol-042718-041407","article-title":"Emerging cellular therapies for cancer","volume":"37","author":"Guedan","year":"2019","journal-title":"Annu Rev. Immunol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib25","doi-asserted-by":"crossref","first-page":"759","DOI":"10.1158\/2326-6066.CIR-18-0466","article-title":"IL15 Enhances CAR-T Cell Antitumor Activity by Reducing mTORC1 Activity and Preserving Their Stem Cell Memory Phenotype","volume":"7","author":"Alizadeh","year":"2019","journal-title":"Cancer Immunol. Res"},{"issue":"48","key":"10.1016\/j.biopha.2023.114609_bib26","doi-asserted-by":"crossref","first-page":"E7788","DOI":"10.1073\/pnas.1610544113","article-title":"Tethered IL-15 augments antitumor activity and promotes a stem-cell memory subset in tumor-specific T cells","volume":"113","author":"Hurton","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib27","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1268","article-title":"Memory stem T cells modified with a redesigned CD30-chimeric antigen receptor show an enhanced antitumor effect in Hodgkin lymphoma","volume":"10","author":"Alvarez-Fernandez","year":"2021","journal-title":"Clin. Transl. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib28","doi-asserted-by":"crossref","first-page":"118","DOI":"10.1186\/s13045-021-01128-9","article-title":"IL-7 and CCL19-secreting CAR-T cell therapy for tumors with positive glypican-3 or mesothelin","volume":"14","author":"Pang","year":"2021","journal-title":"J. Hematol. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib29","doi-asserted-by":"crossref","first-page":"444","DOI":"10.1038\/s41467-020-20599-x","article-title":"Intratumoral IL-12 delivery empowers CAR-T cell immunotherapy in a pre-clinical model of glioblastoma","volume":"12","author":"Agliardi","year":"2021","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib30","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.immuni.2012.09.019","article-title":"Cytokine-mediated programmed proliferation of virus-specific CD8(+) memory T cells","volume":"38","author":"Raue","year":"2013","journal-title":"Immunity"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib31","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1016\/j.ccell.2020.07.005","article-title":"Engineering CAR-T cells for next-generation cancer therapy","volume":"38","author":"Hong","year":"2020","journal-title":"Cancer Cell"},{"issue":"625","key":"10.1016\/j.biopha.2023.114609_bib32","doi-asserted-by":"crossref","first-page":"eabg7565","DOI":"10.1126\/scitranslmed.abg7565","article-title":"An orthogonal IL-2 and IL-2Rbeta system drives persistence and activation of CAR T cells and clearance of bulky lymphoma","volume":"13","author":"Aspuria","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"625","key":"10.1016\/j.biopha.2023.114609_bib33","doi-asserted-by":"crossref","first-page":"eabg6986","DOI":"10.1126\/scitranslmed.abg6986","article-title":"A human orthogonal IL-2 and IL-2Rbeta system enhances CAR T cell expansion and antitumor activity in a murine model of leukemia","volume":"13","author":"Zhang","year":"2021","journal-title":"Sci. Transl. Med"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib34","doi-asserted-by":"crossref","first-page":"613","DOI":"10.1016\/j.cell.2017.01.018","article-title":"Clonal heterogeneity and tumor evolution: past, present, and the future","volume":"168","author":"McGranahan","year":"2017","journal-title":"Cell"},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib35","doi-asserted-by":"crossref","first-page":"2750","DOI":"10.1172\/JCI45014","article-title":"Identification of human triple-negative breast cancer subtypes and preclinical models for selection of targeted therapies","volume":"121","author":"Lehmann","year":"2011","journal-title":"J. Clin. Invest"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib36","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1016\/j.ccell.2019.02.001","article-title":"Genomic and transcriptomic landscape of triple-negative breast cancers: subtypes and treatment strategies","volume":"35","author":"Jiang","year":"2019","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib37","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/nrclinonc.2017.166","article-title":"Tumour heterogeneity and resistance to cancer therapies","volume":"15","author":"Dagogo-Jack","year":"2018","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib38","doi-asserted-by":"crossref","first-page":"755","DOI":"10.1007\/s13402-022-00700-w","article-title":"Immunotherapy and immunoengineering for breast cancer; a comprehensive insight into CAR-T cell therapy advancements, challenges and prospects","volume":"45","author":"Bozorgi","year":"2022","journal-title":"Cell Oncol. (Dordr. )"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib39","doi-asserted-by":"crossref","first-page":"875","DOI":"10.1016\/j.immuni.2021.04.004","article-title":"MDSC: Markers, development, states, and unaddressed complexity","volume":"54","author":"Hegde","year":"2021","journal-title":"Immunity"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib40","doi-asserted-by":"crossref","first-page":"425","DOI":"10.1158\/0008-5472.CAN-06-3037","article-title":"The terminology issue for myeloid-derived suppressor cells","volume":"67","author":"Gabrilovich","year":"2007","journal-title":"Cancer Res"},{"issue":"44","key":"10.1016\/j.biopha.2023.114609_bib41","doi-asserted-by":"crossref","DOI":"10.1126\/sciimmunol.aay6017","article-title":"Defining the emergence of myeloid-derived suppressor cells in breast cancer using single-cell transcriptomics","volume":"5","author":"Alshetaiwi","year":"2020","journal-title":"Sci. Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib42","doi-asserted-by":"crossref","first-page":"49","DOI":"10.1007\/s00262-008-0523-4","article-title":"Increased circulating myeloid-derived suppressor cells correlate with clinical cancer stage, metastatic tumor burden, and doxorubicin-cyclophosphamide chemotherapy","volume":"58","author":"Diaz-Montero","year":"2009","journal-title":"Cancer Immunol. Immunother."},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib43","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001223","article-title":"Differential expansion of circulating human MDSC subsets in patients with cancer, infection and inflammation","volume":"8","author":"Cassetta","year":"2020","journal-title":"J. Immunother. Cancer"},{"key":"10.1016\/j.biopha.2023.114609_bib44","doi-asserted-by":"crossref","first-page":"12150","DOI":"10.1038\/ncomms12150","article-title":"Recommendations for myeloid-derived suppressor cell nomenclature and characterization standards","volume":"7","author":"Bronte","year":"2016","journal-title":"Nat. Commun."},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib45","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-003237","article-title":"Selectively targeting myeloid-derived suppressor cells through TRAIL receptor 2 to enhance the efficacy of CAR T cell therapy for treatment of breast cancer","volume":"9","author":"Nalawade","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"7446","key":"10.1016\/j.biopha.2023.114609_bib46","doi-asserted-by":"crossref","first-page":"445","DOI":"10.1038\/nature12034","article-title":"Macrophage biology in development, homeostasis and disease","volume":"496","author":"Wynn","year":"2013","journal-title":"Nature"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib47","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1038\/s41392-021-00484-9","article-title":"Targeting tumor-associated macrophages to synergize tumor immunotherapy","volume":"6","author":"Xiang","year":"2021","journal-title":"Signal Transduct. Target Ther."},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib48","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/nrclinonc.2016.217","article-title":"Tumour-associated macrophages as treatment targets in oncology","volume":"14","author":"Mantovani","year":"2017","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"13","key":"10.1016\/j.biopha.2023.114609_bib49","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22136995","article-title":"Macrophage Polarization States in the Tumor Microenvironment","volume":"22","author":"Boutilier","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"Pt B","key":"10.1016\/j.biopha.2023.114609_bib50","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/j.addr.2015.11.009","article-title":"Tumor-associated macrophages: Potential therapeutic targets for anti-cancer therapy","volume":"99","author":"Komohara","year":"2016","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib51","doi-asserted-by":"crossref","first-page":"5723","DOI":"10.1158\/0008-5472.CAN-13-2347","article-title":"HMGB1 enhances immune suppression by facilitating the differentiation and suppressive activity of myeloid-derived suppressor cells","volume":"74","author":"Parker","year":"2014","journal-title":"Cancer Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib52","doi-asserted-by":"crossref","first-page":"54","DOI":"10.1158\/2159-8274.CD-10-0028","article-title":"Leukocyte complexity predicts breast cancer survival and functionally regulates response to chemotherapy","volume":"1","author":"DeNardo","year":"2011","journal-title":"Cancer Disco"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib53","doi-asserted-by":"crossref","DOI":"10.1016\/j.celrep.2021.109844","article-title":"Targeting TREM2 on tumor-associated macrophages enhances immunotherapy","volume":"37","author":"Binnewies","year":"2021","journal-title":"Cell Rep."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib54","doi-asserted-by":"crossref","first-page":"147","DOI":"10.1111\/imr.12972","article-title":"Fibroblasts as confederates of the immune system","volume":"302","author":"Correa-Gallegos","year":"2021","journal-title":"Immunol. Rev."},{"issue":"12","key":"10.1016\/j.biopha.2023.114609_bib55","doi-asserted-by":"crossref","first-page":"792","DOI":"10.1038\/s41571-021-00546-5","article-title":"Clinical and therapeutic relevance of cancer-associated fibroblasts","volume":"18","author":"Chen","year":"2021","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"12","key":"10.1016\/j.biopha.2023.114609_bib56","doi-asserted-by":"crossref","first-page":"1640","DOI":"10.4161\/cbt.5.12.3354","article-title":"Identification of fibroblast heterogeneity in the tumor microenvironment","volume":"5","author":"Sugimoto","year":"2006","journal-title":"Cancer Biol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib57","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1038\/nrc.2016.73","article-title":"The biology and function of fibroblasts in cancer","volume":"16","author":"Kalluri","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib58","doi-asserted-by":"crossref","first-page":"174","DOI":"10.1038\/s41568-019-0238-1","article-title":"A framework for advancing our understanding of cancer-associated fibroblasts","volume":"20","author":"Sahai","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib59","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1038\/ng.3818","article-title":"Reference component analysis of single-cell transcriptomes elucidates cellular heterogeneity in human colorectal tumors","volume":"49","author":"Li","year":"2017","journal-title":"Nat. Genet"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib60","doi-asserted-by":"crossref","first-page":"5150","DOI":"10.1038\/s41467-018-07582-3","article-title":"Spatially and functionally distinct subclasses of breast cancer-associated fibroblasts revealed by single cell RNA sequencing","volume":"9","author":"Bartoschek","year":"2018","journal-title":"Nat. Commun."},{"issue":"8","key":"10.1016\/j.biopha.2023.114609_bib61","doi-asserted-by":"crossref","first-page":"1277","DOI":"10.1038\/s41591-018-0096-5","article-title":"Phenotype molding of stromal cells in the lung tumor microenvironment","volume":"24","author":"Lambrechts","year":"2018","journal-title":"Nat. Med"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib62","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1016\/j.cell.2005.02.034","article-title":"Stromal fibroblasts present in invasive human breast carcinomas promote tumor growth and angiogenesis through elevated SDF-1\/CXCL12 secretion","volume":"121","author":"Orimo","year":"2005","journal-title":"Cell"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib63","doi-asserted-by":"crossref","first-page":"4375","DOI":"10.1038\/s41467-019-12370-8","article-title":"NLRP3 inflammasome in fibroblasts links tissue damage with inflammation in breast cancer progression and metastasis","volume":"10","author":"Ershaid","year":"2019","journal-title":"Nat. Commun."},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib64","doi-asserted-by":"crossref","first-page":"834","DOI":"10.1158\/0008-5472.CAN-12-2066","article-title":"Resistance to irreversible EGF receptor tyrosine kinase inhibitors through a multistep mechanism involving the IGF1R pathway","volume":"73","author":"Cortot","year":"2013","journal-title":"Cancer Res"},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib65","doi-asserted-by":"crossref","first-page":"839","DOI":"10.1038\/nrc1477","article-title":"Friends or foes - bipolar effects of the tumour stroma in cancer","volume":"4","author":"Mueller","year":"2004","journal-title":"Nat. Rev. Cancer"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib66","doi-asserted-by":"crossref","first-page":"719","DOI":"10.1016\/j.ccr.2014.04.005","article-title":"Depletion of carcinoma-associated fibroblasts and fibrosis induces immunosuppression and accelerates pancreas cancer with reduced survival","volume":"25","author":"Ozdemir","year":"2014","journal-title":"Cancer Cell"},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib67","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.trecan.2020.02.003","article-title":"Cancer epigenetics, tumor immunity, and immunotherapy","volume":"6","author":"Cao","year":"2020","journal-title":"Trends Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2023.114609_bib68","doi-asserted-by":"crossref","DOI":"10.1016\/j.cell.2022.09.027","article-title":"SnapShot: Cancer immunoediting","volume":"185","author":"Varanasi","year":"2022","journal-title":"Cell"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib69","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1038\/s41571-018-0142-8","article-title":"Cancer immunoediting and resistance to T cell-based immunotherapy","volume":"16","author":"O'Donnell","year":"2019","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.biopha.2023.114609_bib70","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.636568","article-title":"Cancer Immune Evasion Through Loss of MHC Class I Antigen Presentation","volume":"12","author":"Dhatchinamoorthy","year":"2021","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib71","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1007\/s00262-009-0803-7","article-title":"Patients with oral squamous cell carcinoma are characterized by increased frequency of suppressive regulatory T cells in the blood and tumor microenvironment","volume":"59","author":"Gasparoto","year":"2010","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib72","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/cr.2016.151","article-title":"Regulatory T cells in cancer immunotherapy","volume":"27","author":"Tanaka","year":"2017","journal-title":"Cell Res"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib73","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/j.canlet.2013.01.001","article-title":"Inhibition of TGF-beta signaling in combination with TLR7 ligation re-programs a tumoricidal phenotype in tumor-associated macrophages","volume":"331","author":"Peng","year":"2013","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib74","doi-asserted-by":"crossref","first-page":"2452","DOI":"10.1016\/j.ymthe.2017.07.013","article-title":"Function of Novel Anti-CD19 Chimeric Antigen Receptors with Human Variable Regions Is Affected by Hinge and Transmembrane Domains","volume":"25","author":"Alabanza","year":"2017","journal-title":"Mol. Ther."},{"key":"10.1016\/j.biopha.2023.114609_bib75","article-title":"Induction of heparanase via IL-10 correlates with a high infiltration of CD163+ M2-type tumor-associated macrophages in inflammatory breast carcinomas","volume":"6\u20137","author":"El-Nadi","year":"2020","journal-title":"Matrix Biol."},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib76","doi-asserted-by":"crossref","first-page":"32722","DOI":"10.18632\/oncotarget.16281","article-title":"Tumor-derived IL-18 induces PD-1 expression on immunosuppressive NK cells in triple-negative breast cancer","volume":"8","author":"Park","year":"2017","journal-title":"Oncotarget"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib77","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1038\/s41590-019-0389-y","article-title":"T(reg) cell IL-10 and IL-35 exhaust CD8(+) T cells in tumors","volume":"20","author":"Damo","year":"2019","journal-title":"Nat. Immunol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib78","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1245\/ASO.2004.05.027","article-title":"Reduced T-cell and dendritic cell function is related to cyclooxygenase-2 overexpression and prostaglandin E2 secretion in patients with breast cancer","volume":"11","author":"Pockaj","year":"2004","journal-title":"Ann. Surg. Oncol."},{"key":"10.1016\/j.biopha.2023.114609_bib79","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2022.883733","article-title":"Co-Inhibitory Molecules - Their Role in Health and Autoimmunity; Highlighted by Immune Related Adverse Events","volume":"13","author":"Greisen","year":"2022","journal-title":"Front Immunol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib80","doi-asserted-by":"crossref","DOI":"10.1016\/j.bbcan.2021.188569","article-title":"Targeting Bcl-2 for cancer therapy","volume":"1876","author":"Zhang","year":"2021","journal-title":"Biochim Biophys. Acta Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib81","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1038\/nrc.2015.17","article-title":"Thirty years of BCL-2: translating cell death discoveries into novel cancer therapies","volume":"16","author":"Delbridge","year":"2016","journal-title":"Nat. Rev. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib82","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1038\/s41568-020-0263-0","article-title":"The dormant cancer cell life cycle","volume":"20","author":"Phan","year":"2020","journal-title":"Nat. Rev. Cancer"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib83","doi-asserted-by":"crossref","first-page":"375","DOI":"10.1016\/j.devcel.2019.04.012","article-title":"Metastasis organotropism: redefining the congenial soil","volume":"49","author":"Gao","year":"2019","journal-title":"Dev. Cell"},{"issue":"10","key":"10.1016\/j.biopha.2023.114609_bib84","doi-asserted-by":"crossref","first-page":"3237","DOI":"10.1002\/jcb.25972","article-title":"Metastatic breast cancer cells enter into dormant state and express cancer stem cells phenotype under chronic hypoxia","volume":"118","author":"Carcereri de Prati","year":"2017","journal-title":"J. Cell Biochem"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib85","doi-asserted-by":"crossref","first-page":"4533","DOI":"10.1038\/s41467-019-12296-1","article-title":"Transcriptomic profiling of the myeloma bone-lining niche reveals BMP signalling inhibition to improve bone disease","volume":"10","author":"Gooding","year":"2019","journal-title":"Nat. Commun."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib86","doi-asserted-by":"crossref","first-page":"76","DOI":"10.1186\/s12943-017-0646-3","article-title":"Emerging roles of lipid metabolism in cancer metastasis","volume":"16","author":"Luo","year":"2017","journal-title":"Mol. Cancer"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib87","doi-asserted-by":"crossref","first-page":"178","DOI":"10.1172\/JCI58128","article-title":"Epoxyeicosanoids stimulate multiorgan metastasis and tumor dormancy escape in mice","volume":"122","author":"Panigrahy","year":"2012","journal-title":"J. Clin. Invest"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib88","doi-asserted-by":"crossref","first-page":"274","DOI":"10.1038\/nrc2622","article-title":"Metastasis: from dissemination to organ-specific colonization","volume":"9","author":"Nguyen","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib89","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1593\/neo.91384","article-title":"GAS6\/AXL axis regulates prostate cancer invasion, proliferation, and survival in the bone marrow niche","volume":"12","author":"Shiozawa","year":"2010","journal-title":"Neoplasia"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib90","doi-asserted-by":"crossref","first-page":"766","DOI":"10.1038\/s41467-019-08595-2","article-title":"Barcoding reveals complex clonal behavior in patient-derived xenografts of metastatic triple negative breast cancer","volume":"10","author":"Merino","year":"2019","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.biopha.2023.114609_bib91","doi-asserted-by":"crossref","first-page":"1024","DOI":"10.1158\/2159-8290.CD-15-0507","article-title":"MYC, Metabolism, and Cancer","volume":"5","author":"Stine","year":"2015","journal-title":"Cancer Disco"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib92","doi-asserted-by":"crossref","first-page":"116","DOI":"10.1186\/s13058-020-01357-9","article-title":"Local and distant tumor dormancy during early stage breast cancer are associated with the predominance of infiltrating T effector subsets","volume":"22","author":"Aqbi","year":"2020","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.biopha.2023.114609_bib93","doi-asserted-by":"crossref","DOI":"10.7554\/eLife.80315","article-title":"Transient cell-in-cell formation underlies tumor relapse and resistance to immunotherapy","volume":"11","author":"Gutwillig","year":"2022","journal-title":"Elife"},{"issue":"12","key":"10.1016\/j.biopha.2023.114609_bib94","doi-asserted-by":"crossref","first-page":"3061","DOI":"10.1158\/1078-0432.CCR-16-2083","article-title":"Analysis of ROR1 Protein Expression in Human Cancer and Normal Tissues","volume":"23","author":"Balakrishnan","year":"2017","journal-title":"Clin. Cancer Res"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib95","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1007\/s00428-016-1911-3","article-title":"Expression of ROR1 has prognostic significance in triple negative breast cancer","volume":"468","author":"Chien","year":"2016","journal-title":"Virchows Arch."},{"key":"10.1016\/j.biopha.2023.114609_bib96","doi-asserted-by":"crossref","first-page":"5811","DOI":"10.1038\/srep05811","article-title":"ROR1 expression correlated with poor clinical outcome in human ovarian cancer","volume":"4","author":"Zhang","year":"2014","journal-title":"Sci. Rep."},{"issue":"48","key":"10.1016\/j.biopha.2023.114609_bib97","doi-asserted-by":"crossref","first-page":"17266","DOI":"10.1073\/pnas.1419599111","article-title":"Ovarian cancer stem cells express ROR1, which can be targeted for anti-cancer-stem-cell therapy","volume":"111","author":"Zhang","year":"2014","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib98","doi-asserted-by":"crossref","first-page":"348","DOI":"10.1016\/j.ccr.2012.02.008","article-title":"NKX2-1\/TITF1\/TTF-1-Induced ROR1 is required to sustain EGFR survival signaling in lung adenocarcinoma","volume":"21","author":"Yamaguchi","year":"2012","journal-title":"Cancer Cell"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib99","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1158\/2326-6066.CIR-14-0163","article-title":"Safety of targeting ROR1 in primates with chimeric antigen receptor-modified T cells","volume":"3","author":"Berger","year":"2015","journal-title":"Cancer Immunol. Res"},{"issue":"18","key":"10.1016\/j.biopha.2023.114609_bib100","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.126345","article-title":"ROR1-CAR T cells are effective against lung and breast cancer in advanced microphysiologic 3D tumor models","volume":"4","author":"Wallstabe","year":"2019","journal-title":"JCI Insight"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib101","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-000676","article-title":"Inhibition of TGF-beta-receptor signaling augments the antitumor function of ROR1-specific CAR T-cells against triple-negative breast cancer","volume":"8","author":"Stuber","year":"2020","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib102","doi-asserted-by":"crossref","first-page":"317","DOI":"10.1007\/s10549-008-0206-z","article-title":"Invasive ductal carcinoma of the breast with the \"triple-negative\" phenotype: prognostic implications of EGFR immunoreactivity","volume":"116","author":"Viale","year":"2009","journal-title":"Breast Cancer Res Treat."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib103","doi-asserted-by":"crossref","first-page":"1212","DOI":"10.1038\/modpathol.2013.251","article-title":"High EGFR gene copy number predicts poor outcome in triple-negative breast cancer","volume":"27","author":"Park","year":"2014","journal-title":"Mod. Pathol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib104","doi-asserted-by":"crossref","first-page":"862","DOI":"10.1093\/annonc\/mdn710","article-title":"Epidermal growth factor receptor as a potential therapeutic target in triple-negative breast cancer","volume":"20","author":"Corkery","year":"2009","journal-title":"Ann. Oncol."},{"issue":"14","key":"10.1016\/j.biopha.2023.114609_bib105","article-title":"SGCE Promotes Breast Cancer Stem Cells by Stabilizing EGFR","volume":"7","author":"Zhao","year":"2020","journal-title":"Adv. Sci. (Weinh. )"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib106","doi-asserted-by":"crossref","first-page":"1112","DOI":"10.1038\/s41388-019-1046-5","article-title":"HUNK phosphorylates EGFR to regulate breast cancer metastasis","volume":"39","author":"Williams","year":"2020","journal-title":"Oncogene"},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib107","doi-asserted-by":"crossref","first-page":"2586","DOI":"10.1200\/JCO.2012.46.2408","article-title":"Randomized phase II study of the anti-epidermal growth factor receptor monoclonal antibody cetuximab with cisplatin versus cisplatin alone in patients with metastatic triple-negative breast cancer","volume":"31","author":"Baselga","year":"2013","journal-title":"J. Clin. Oncol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114609_bib108","doi-asserted-by":"crossref","first-page":"1570","DOI":"10.1093\/annonc\/mdu183","article-title":"Multicentric neoadjuvant phase II study of panitumumab combined with an anthracycline\/taxane-based chemotherapy in operable triple-negative breast cancer: identification of biologically defined signatures predicting treatment impact","volume":"25","author":"Nabholtz","year":"2014","journal-title":"Ann. Oncol."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib109","doi-asserted-by":"crossref","first-page":"23","DOI":"10.1016\/j.clbc.2015.08.002","article-title":"N0436 (Alliance): A Phase II Trial of Irinotecan With Cetuximab in Patients With Metastatic Breast Cancer Previously Exposed to Anthracycline and\/or Taxane-Containing Therapy","volume":"16","author":"Crozier","year":"2016","journal-title":"Clin. Breast Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib110","doi-asserted-by":"crossref","DOI":"10.1002\/cti2.1135","article-title":"EGFR-targeted CAR-T cells are potent and specific in suppressing triple-negative breast cancer both in vitro and in vivo","volume":"9","author":"Xia","year":"2020","journal-title":"Clin. Transl. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib111","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1158\/2326-6066.CIR-20-0405","article-title":"Targeting Triple-Negative Breast Cancer with Combination Therapy of EGFR CAR T Cells and CDK7 Inhibition","volume":"9","author":"Xia","year":"2021","journal-title":"Cancer Immunol. Res"},{"issue":"12","key":"10.1016\/j.biopha.2023.114609_bib112","doi-asserted-by":"crossref","first-page":"874","DOI":"10.1038\/nrc2761","article-title":"Mucins in cancer: function, prognosis and therapy","volume":"9","author":"Kufe","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"15","key":"10.1016\/j.biopha.2023.114609_bib113","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23158219","article-title":"Addiction of Cancer Stem Cells to MUC1-C in Triple-Negative Breast Cancer Progression","volume":"23","author":"Yamashita","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"1\u20132","key":"10.1016\/j.biopha.2023.114609_bib114","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10555-018-09775-0","article-title":"Cancer-associated mucins: role in immune modulation and metastasis","author":"Bhatia","year":"2019","journal-title":"Cancer Metastas-.-. Rev. 38("},{"issue":"Suppl 1","key":"10.1016\/j.biopha.2023.114609_bib115","doi-asserted-by":"crossref","first-page":"S81","DOI":"10.1093\/annonc\/12.suppl_1.S81","article-title":"Targeting HER2 in other tumor types","volume":"12","author":"Scholl","year":"2001","journal-title":"Ann. Oncol."},{"issue":"10074","key":"10.1016\/j.biopha.2023.114609_bib116","doi-asserted-by":"crossref","first-page":"1134","DOI":"10.1016\/S0140-6736(16)31891-8","article-title":"Breast cancer","volume":"389","author":"Harbeck","year":"2017","journal-title":"Lancet"},{"issue":"10251","key":"10.1016\/j.biopha.2023.114609_bib117","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1016\/S0140-6736(20)31288-5","article-title":"Gastric cancer","volume":"396","author":"Smyth","year":"2020","journal-title":"Lancet"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib118","doi-asserted-by":"crossref","first-page":"531","DOI":"10.1080\/13543784.2017.1315406","article-title":"Perspectives of HER2-targeting in gastric and esophageal cancer","volume":"26","author":"Gerson","year":"2017","journal-title":"Expert Opin. Invest. Drugs"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib119","doi-asserted-by":"crossref","first-page":"779","DOI":"10.1016\/S1470-2045(21)00086-3","article-title":"D.-C. investigators, Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial","volume":"22","author":"Siena","year":"2021","journal-title":"Lancet Oncol."},{"key":"10.1016\/j.biopha.2023.114609_bib120","doi-asserted-by":"crossref","DOI":"10.1016\/j.scitotenv.2020.141962","article-title":"Arsenic-induced HER2 promotes proliferation, migration and angiogenesis of bladder epithelial cells via activation of multiple signaling pathways in vitro and in vivo","volume":"753","author":"Zhou","year":"2021","journal-title":"Sci. Total Environ."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib121","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1056\/NEJMoa2112431","article-title":"Trastuzumab Deruxtecan in HER2-Mutant Non-Small-Cell Lung Cancer","volume":"386","author":"Li","year":"2022","journal-title":"N. Engl. J. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib122","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/s41571-019-0268-3","article-title":"HER2-targeted therapies - a role beyond breast cancer","volume":"17","author":"Oh","year":"2020","journal-title":"Nat. Rev. Clin. Oncol."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib123","doi-asserted-by":"crossref","DOI":"10.1136\/esmoopen-2017-000279","article-title":"Activating HER2 mutations as emerging targets in multiple solid cancers","volume":"2","author":"Connell","year":"2017","journal-title":"ESMO Open"},{"key":"10.1016\/j.biopha.2023.114609_bib124","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.canlet.2020.04.008","article-title":"Trastuzumab derived HER2-specific CARs for the treatment of trastuzumab-resistant breast cancer: CAR T cells penetrate and eradicate tumors that are not accessible to antibodies","volume":"484","author":"Szoor","year":"2020","journal-title":"Cancer Lett."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib125","doi-asserted-by":"crossref","DOI":"10.3390\/ijms21031039","article-title":"Number of HER2 Redirected CAR T Cells Significantly Improves Immune Response of Adoptively Transferred Mouse Lymphocytes against Human Breast Cancer Xenografts","volume":"21","author":"Toth","year":"2020","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.114609_bib126","doi-asserted-by":"crossref","first-page":"121","DOI":"10.1016\/j.canlet.2021.10.016","article-title":"IKZF3 deficiency potentiates chimeric antigen receptor T cells targeting solid tumors","volume":"524","author":"Zou","year":"2022","journal-title":"Cancer Lett."},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib127","doi-asserted-by":"crossref","first-page":"1418","DOI":"10.1097\/00000478-200311000-00003","article-title":"Application of mesothelin immunostaining in tumor diagnosis","volume":"27","author":"Ordonez","year":"2003","journal-title":"Am. J. Surg. Pathol."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib128","doi-asserted-by":"crossref","first-page":"192","DOI":"10.1097\/01.MP.0000056981.16578.C3","article-title":"Value of mesothelin immunostaining in the diagnosis of mesothelioma","volume":"16","author":"Ordonez","year":"2003","journal-title":"Mod. Pathol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib129","doi-asserted-by":"crossref","first-page":"767","DOI":"10.1111\/j.1365-2559.2005.02279.x","article-title":"The use of the monoclonal antibody mesothelin in the diagnosis of malignant mesothelioma in pleural biopsies","volume":"48","author":"Galloway","year":"2006","journal-title":"Histopathology"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib130","doi-asserted-by":"crossref","first-page":"1571","DOI":"10.1158\/1078-0432.CCR-06-2161","article-title":"Mesothelin expression in human lung cancer","volume":"13","author":"Ho","year":"2007","journal-title":"Clin. Cancer Res"},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib131","doi-asserted-by":"crossref","first-page":"2128","DOI":"10.1084\/jem.20190249","article-title":"Single-cell transcriptomic analysis of tissue-resident memory T cells in human lung cancer","volume":"216","author":"Clarke","year":"2019","journal-title":"J. Exp. Med"},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib132","doi-asserted-by":"crossref","first-page":"3022","DOI":"10.1158\/0008-5472.CAN-20-2701","article-title":"Mesothelin-specific CAR T cells target ovarian cancer","volume":"81","author":"Schoutrop","year":"2021","journal-title":"Cancer Res"},{"issue":"22","key":"10.1016\/j.biopha.2023.114609_bib133","doi-asserted-by":"crossref","DOI":"10.3390\/ijms222212443","article-title":"Host mesothelin expression increases ovarian cancer metastasis in the peritoneal microenvironment","volume":"22","author":"Hilliard","year":"2021","journal-title":"Int J. Mol. Sci."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib134","doi-asserted-by":"crossref","first-page":"18","DOI":"10.1186\/s13045-019-0704-y","article-title":"Mesothelin is a target of chimeric antigen receptor T cells for treating gastric cancer","volume":"12","author":"Lv","year":"2019","journal-title":"J. Hematol. Oncol."},{"key":"10.1016\/j.biopha.2023.114609_bib135","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.biopha.2015.01.019","article-title":"Prognostic value of mesothelin expression in patients with triple negative and HER2-positive breast cancers","volume":"70","author":"Bayoglu","year":"2015","journal-title":"Biomed. Pharm."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib136","first-page":"3759","article-title":"PTK7 expression in triple-negative breast cancer","volume":"33","author":"Ataseven","year":"2013","journal-title":"Anticancer Res"},{"issue":"34","key":"10.1016\/j.biopha.2023.114609_bib137","doi-asserted-by":"crossref","first-page":"4171","DOI":"10.1200\/JCO.2016.68.3672","article-title":"Mesothelin immunotherapy for cancer: ready for prime time?","volume":"34","author":"Hassan","year":"2016","journal-title":"J. Clin. Oncol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib138","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1080\/14712598.2021.1843628","article-title":"Mesothelin-targeted CAR-T cell therapy for solid tumors","volume":"21","author":"Klampatsa","year":"2021","journal-title":"Expert Opin. Biol. Ther."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib139","doi-asserted-by":"crossref","first-page":"365","DOI":"10.1007\/s00262-018-2281-2","article-title":"CRISPR\/Cas9-mediated PD-1 disruption enhances human mesothelin-targeted CAR T cell effector functions","volume":"68","author":"Hu","year":"2019","journal-title":"Cancer Immunol. Immunother."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib140","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1016\/j.abb.2011.12.019","article-title":"The many roles of PTK7: a versatile regulator of cell-cell communication","volume":"524","author":"Peradziryi","year":"2012","journal-title":"Arch. Biochem Biophys."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib141","doi-asserted-by":"crossref","first-page":"443","DOI":"10.1016\/j.tcb.2006.07.003","article-title":"Emerging roles of pseudokinases","volume":"16","author":"Boudeau","year":"2006","journal-title":"Trends Cell Biol."},{"issue":"18","key":"10.1016\/j.biopha.2023.114609_bib142","doi-asserted-by":"crossref","first-page":"3729","DOI":"10.1038\/emboj.2011.236","article-title":"PTK7\/Otk interacts with Wnts and inhibits canonical Wnt signalling","volume":"30","author":"Peradziryi","year":"2011","journal-title":"EMBO J."},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib143","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pgen.1004443","article-title":"The PTK7-related transmembrane proteins off-track and off-track 2 are co-receptors for Drosophila Wnt2 required for male fertility","volume":"10","author":"Linnemannstons","year":"2014","journal-title":"PLoS Genet"},{"issue":"51","key":"10.1016\/j.biopha.2023.114609_bib144","doi-asserted-by":"crossref","first-page":"30562","DOI":"10.1074\/jbc.M115.697615","article-title":"The PTK7 and ROR2 Protein Receptors Interact in the Vertebrate WNT\/Planar Cell Polarity (PCP) Pathway","volume":"290","author":"Martinez","year":"2015","journal-title":"J. Biol. Chem."},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib145","doi-asserted-by":"crossref","DOI":"10.3390\/ijms23031295","article-title":"Whole-Exome Sequencing Identifies a Novel Germline Variant in PTK7 Gene in Familial Colorectal Cancer","volume":"23","author":"Miao","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib146","doi-asserted-by":"crossref","first-page":"505","DOI":"10.1093\/neuonc\/nou227","article-title":"PTK7 regulates Id1 expression in CD44-high glioma cells","volume":"17","author":"Liu","year":"2015","journal-title":"Neuro Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib147","doi-asserted-by":"crossref","DOI":"10.3390\/ijms232012195","article-title":"Anti-PTK7 Monoclonal Antibodies Exhibit Anti-Tumor Activity at the Cellular Level and in Mouse Xenograft Models of Esophageal Squamous Cell Carcinoma","volume":"23","author":"Kim","year":"2022","journal-title":"Int J. Mol. Sci."},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib148","doi-asserted-by":"crossref","first-page":"11665","DOI":"10.3390\/ijms150711665","article-title":"Protein tyrosine kinase 7 (PTK7) as a predictor of lymph node metastases and a novel prognostic biomarker in patients with prostate cancer","volume":"15","author":"Zhang","year":"2014","journal-title":"Int J. Mol. Sci."},{"key":"10.1016\/j.biopha.2023.114609_bib149","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2021.699889","article-title":"Protein Tyrosine Kinase 7 Regulates EGFR\/Akt Signaling Pathway and Correlates With Malignant Progression in Triple-Negative Breast Cancer","volume":"11","author":"Cui","year":"2021","journal-title":"Front Oncol."},{"key":"10.1016\/j.biopha.2023.114609_bib150","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.665970","article-title":"PTK7-Targeting CAR T-Cells for the Treatment of Lung Cancer and Other Malignancies","volume":"12","author":"Jie","year":"2021","journal-title":"Front Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib151","doi-asserted-by":"crossref","first-page":"2708","DOI":"10.3892\/or.2014.3164","article-title":"Protein tyrosine kinase 7 plays a tumor suppressor role by inhibiting ERK and AKT phosphorylation in lung cancer","volume":"31","author":"Kim","year":"2014","journal-title":"Oncol. Rep."},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib152","first-page":"7881","article-title":"PTK7 protein is decreased in epithelial ovarian carcinomas with poor prognosis","volume":"7","author":"Wang","year":"2014","journal-title":"Int J. Clin. Exp. Pathol."},{"issue":"18","key":"10.1016\/j.biopha.2023.114609_bib153","doi-asserted-by":"crossref","DOI":"10.3390\/cancers14184463","article-title":"Anti-PTK7 monoclonal antibodies inhibit angiogenesis by suppressing PTK7 function","volume":"14","author":"Oh","year":"2022","journal-title":"Cancers (Basel)"},{"issue":"372","key":"10.1016\/j.biopha.2023.114609_bib154","doi-asserted-by":"crossref","DOI":"10.1126\/scitranslmed.aag2611","article-title":"A PTK7-targeted antibody-drug conjugate reduces tumor-initiating cells and induces sustained tumor regressions","volume":"9","author":"Damelin","year":"2017","journal-title":"Sci. Transl. Med"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib155","doi-asserted-by":"crossref","first-page":"881","DOI":"10.1083\/jcb.200403174","article-title":"Melanoma chondroitin sulfate proteoglycan enhances FAK and ERK activation by distinct mechanisms","volume":"165","author":"Yang","year":"2004","journal-title":"J. Cell Biol."},{"issue":"19","key":"10.1016\/j.biopha.2023.114609_bib156","doi-asserted-by":"crossref","first-page":"7538","DOI":"10.1158\/0008-5472.CAN-08-4626","article-title":"Melanoma proteoglycan modifies gene expression to stimulate tumor cell motility, growth, and epithelial-to-mesenchymal transition","volume":"69","author":"Yang","year":"2009","journal-title":"Cancer Res"},{"issue":"18","key":"10.1016\/j.biopha.2023.114609_bib157","doi-asserted-by":"crossref","first-page":"9710","DOI":"10.1073\/pnas.93.18.9710","article-title":"Molecular cloning of a human melanoma-associated chondroitin sulfate proteoglycan","volume":"93","author":"Pluschke","year":"1996","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4743","key":"10.1016\/j.biopha.2023.114609_bib158","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1126\/science.3633135","article-title":"Human melanoma proteoglycan: expression in hybrids controlled by intrinsic and extrinsic signals","volume":"231","author":"Rettig","year":"1986","journal-title":"Science"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib159","doi-asserted-by":"crossref","first-page":"3112","DOI":"10.1096\/fj.201801670R","article-title":"Structural deciphering of the NG2\/CSPG4 proteoglycan multifunctionality","volume":"33","author":"Tamburini","year":"2019","journal-title":"FASEB J."},{"key":"10.1016\/j.biopha.2023.114609_bib160","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1016\/j.pharmthera.2014.10.001","article-title":"FAK signaling in human cancer as a target for therapeutics","volume":"146","author":"Lee","year":"2015","journal-title":"Pharm. Ther."},{"issue":"8\u20139","key":"10.1016\/j.biopha.2023.114609_bib161","doi-asserted-by":"crossref","first-page":"1085","DOI":"10.1016\/S1357-2725(97)00051-4","article-title":"Role of focal adhesion kinase in integrin signaling","volume":"29","author":"Guan","year":"1997","journal-title":"Int J. Biochem Cell Biol."},{"issue":"19","key":"10.1016\/j.biopha.2023.114609_bib162","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1093\/jnci\/djq343","article-title":"CSPG4 protein as a new target for the antibody-based immunotherapy of triple-negative breast cancer","volume":"102","author":"Wang","year":"2010","journal-title":"J. Natl. Cancer Inst."},{"key":"10.1016\/j.biopha.2023.114609_bib163","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1016\/j.imlet.2019.05.003","article-title":"The UniCAR system: A modular CAR T cell approach to improve the safety of CAR T cells","volume":"211","author":"Bachmann","year":"2019","journal-title":"Immunol. Lett."},{"issue":"8","key":"10.1016\/j.biopha.2023.114609_bib164","doi-asserted-by":"crossref","DOI":"10.1038\/bcj.2016.61","article-title":"Switching CAR T cells on and off: a novel modular platform for retargeting of T cells to AML blasts","volume":"6","author":"Cartellieri","year":"2016","journal-title":"Blood Cancer J."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib165","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1038\/s41408-018-0113-4","article-title":"Development of a novel target module redirecting UniCAR T cells to Sialyl Tn-expressing tumor cells","volume":"8","author":"Loureiro","year":"2018","journal-title":"Blood Cancer J."},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib166","doi-asserted-by":"crossref","first-page":"77","DOI":"10.1186\/s13046-020-01572-4","article-title":"Extended half-life target module for sustainable UniCAR T-cell treatment of STn-expressing cancers","volume":"39","author":"Loureiro","year":"2020","journal-title":"J. Exp. Clin. Cancer Res"},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib167","doi-asserted-by":"crossref","first-page":"339","DOI":"10.1016\/j.blre.2018.02.004","article-title":"Bispecific antibody based therapeutics: Strengths and challenges","volume":"32","author":"Thakur","year":"2018","journal-title":"Blood Rev."},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib168","doi-asserted-by":"crossref","first-page":"7989","DOI":"10.1073\/pnas.83.20.7989","article-title":"Advantages of bispecific hybridomas in one-step immunocytochemistry and immunoassays","volume":"83","author":"Suresh","year":"1986","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"4708","key":"10.1016\/j.biopha.2023.114609_bib169","doi-asserted-by":"crossref","first-page":"81","DOI":"10.1126\/science.3925553","article-title":"Preparation of bispecific antibodies by chemical recombination of monoclonal immunoglobulin G1 fragments","volume":"229","author":"Brennan","year":"1985","journal-title":"Science"},{"issue":"6012","key":"10.1016\/j.biopha.2023.114609_bib170","doi-asserted-by":"crossref","first-page":"628","DOI":"10.1038\/314628a0","article-title":"Hybrid antibodies can target sites for attack by T cells","volume":"314","author":"Staerz","year":"1985","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib171","doi-asserted-by":"crossref","first-page":"1686","DOI":"10.1084\/jem.160.6.1686","article-title":"Production of target-specific effector cells using hetero-cross-linked aggregates containing anti-target cell and anti-Fc gamma receptor antibodies","volume":"160","author":"Karpovsky","year":"1984","journal-title":"J. Exp. Med"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib172","doi-asserted-by":"crossref","first-page":"539","DOI":"10.4161\/mabs.1.6.10015","article-title":"Bispecific antibodies for cancer therapy: the light at the end of the tunnel?","volume":"1","author":"Chames","year":"2009","journal-title":"MAbs"},{"key":"10.1016\/j.biopha.2023.114609_bib173","doi-asserted-by":"crossref","DOI":"10.3389\/fimmu.2021.690437","article-title":"Bispecific Antibody Armed Metabolically Enhanced Headless CAR T Cells","volume":"12","author":"Thakur","year":"2021","journal-title":"Front Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib174","doi-asserted-by":"crossref","first-page":"E459","DOI":"10.1073\/pnas.1524155113","article-title":"Switch-mediated activation and retargeting of CAR-T cells for B-cell malignancies","volume":"113","author":"Rodgers","year":"2016","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"46","key":"10.1016\/j.biopha.2023.114609_bib175","doi-asserted-by":"crossref","first-page":"E10898","DOI":"10.1073\/pnas.1810060115","article-title":"Switchable control over in vivo CAR T expansion, B cell depletion, and induction of memory","volume":"115","author":"Viaud","year":"2018","journal-title":"Proc. Natl. Acad. Sci. USA"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib176","doi-asserted-by":"crossref","first-page":"1176","DOI":"10.1021\/acssynbio.1c00007","article-title":"Switchable CAR-T cells outperformed traditional antibody-redirected therapeutics targeting breast cancers","volume":"10","author":"Cao","year":"2021","journal-title":"ACS Synth. Biol."},{"issue":"7794","key":"10.1016\/j.biopha.2023.114609_bib177","doi-asserted-by":"crossref","first-page":"229","DOI":"10.1038\/s41586-020-1978-5","article-title":"The promise and challenge of therapeutic genome editing","volume":"578","author":"Doudna","year":"2020","journal-title":"Nature"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib178","doi-asserted-by":"crossref","first-page":"430","DOI":"10.1038\/mt.2016.10","article-title":"Genome-editing technologies for gene and cell therapy","volume":"24","author":"Maeder","year":"2016","journal-title":"Mol. Ther."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib179","doi-asserted-by":"crossref","first-page":"1738","DOI":"10.1038\/mt.2013.117","article-title":"Meganuclease-mediated virus self-cleavage facilitates tumor-specific virus replication","volume":"21","author":"Gurlevik","year":"2013","journal-title":"Mol. Ther."},{"issue":"5147","key":"10.1016\/j.biopha.2023.114609_bib180","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1126\/science.8303274","article-title":"Zinc finger phage: affinity selection of fingers with new DNA-binding specificities","volume":"263","author":"Rebar","year":"1994","journal-title":"Science"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib181","doi-asserted-by":"crossref","first-page":"143","DOI":"10.1038\/nbt.1755","article-title":"nuclease architecture for efficient genome editing","volume":"29","author":"Miller","year":"2011","journal-title":"Nat. Biotechnol."},{"issue":"6121","key":"10.1016\/j.biopha.2023.114609_bib182","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1126\/science.1231143","article-title":"Multiplex genome engineering using CRISPR\/Cas systems","volume":"339","author":"Cong","year":"2013","journal-title":"Science"},{"issue":"10","key":"10.1016\/j.biopha.2023.114609_bib183","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1056\/NEJMra1800729","article-title":"Class of Medicines through DNA Editing","volume":"380","author":"Porteus","year":"2019","journal-title":"N. Engl. J. Med"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib184","doi-asserted-by":"crossref","first-page":"818","DOI":"10.1016\/j.ccell.2020.05.004","article-title":"Multi-phenotype CRISPR-Cas9 Screen Identifies p38 Kinase as a Target for Adoptive Immunotherapies","volume":"37","author":"Gurusamy","year":"2020","journal-title":"Cancer Cell"},{"issue":"6481","key":"10.1016\/j.biopha.2023.114609_bib185","doi-asserted-by":"crossref","DOI":"10.1126\/science.aba7365","article-title":"CRISPR-engineered T cells in patients with refractory cancer","volume":"367","author":"Stadtmauer","year":"2020","journal-title":"Science"},{"issue":"6620","key":"10.1016\/j.biopha.2023.114609_bib186","doi-asserted-by":"crossref","DOI":"10.1126\/science.abn5647","article-title":"Enhanced T cell effector activity by targeting the Mediator kinase module","volume":"378","author":"Freitas","year":"2022","journal-title":"Science"},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib187","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0080437","article-title":"Immunomodulatory effects in a phase II study of lenalidomide combined with cetuximab in refractory KRAS-mutant metastatic colorectal cancer patients","volume":"8","author":"Gandhi","year":"2013","journal-title":"PLoS One"},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib188","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1111\/bjh.12708","article-title":"Immunomodulatory agents lenalidomide and pomalidomide co-stimulate T cells by inducing degradation of T cell repressors Ikaros and Aiolos via modulation of the E3 ubiquitin ligase complex CRL4(CRBN.)","volume":"164","author":"Gandhi","year":"2014","journal-title":"Br. J. Haematol."},{"key":"10.1016\/j.biopha.2023.114609_bib189","doi-asserted-by":"crossref","first-page":"515","DOI":"10.1146\/annurev.immunol.23.021704.115611","article-title":"The B7 family revisited","volume":"23","author":"Greenwald","year":"2005","journal-title":"Annu Rev. Immunol."},{"issue":"6","key":"10.1016\/j.biopha.2023.114609_bib190","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1038\/nri2326","article-title":"Inhibitory B7-family molecules in the tumour microenvironment","volume":"8","author":"Zou","year":"2008","journal-title":"Nat. Rev. Immunol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib191","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1038\/nrc3239","article-title":"The blockade of immune checkpoints in cancer immunotherapy","volume":"12","author":"Pardoll","year":"2012","journal-title":"Nat. Rev. Cancer"},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib192","doi-asserted-by":"crossref","first-page":"471","DOI":"10.1016\/j.ccell.2019.09.006","article-title":"Combination Immunotherapy with CAR T Cells and Checkpoint Blockade for the Treatment of Solid Tumors","volume":"36","author":"Grosser","year":"2019","journal-title":"Cancer Cell"},{"issue":"3","key":"10.1016\/j.biopha.2023.114609_bib193","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2020-001536","article-title":"Tumor-derived ILT4 induces T cell senescence and suppresses tumor immunity","volume":"9","author":"Gao","year":"2021","journal-title":"J. Immunother. Cancer"},{"issue":"21","key":"10.1016\/j.biopha.2023.114609_bib194","doi-asserted-by":"crossref","first-page":"2040","DOI":"10.1056\/NEJMoa1810865","article-title":"Pembrolizumab plus Chemotherapy for Squamous Non-Small-Cell Lung Cancer","volume":"379","author":"Paz-Ares","year":"2018","journal-title":"N. Engl. J. Med"},{"issue":"15","key":"10.1016\/j.biopha.2023.114609_bib195","doi-asserted-by":"crossref","first-page":"1600","DOI":"10.1001\/jama.2016.4059","article-title":"Association of pembrolizumab with tumor response and survival among patients with advanced melanoma","volume":"315","author":"Ribas","year":"2016","journal-title":"JAMA"},{"issue":"14","key":"10.1016\/j.biopha.2023.114609_bib196","doi-asserted-by":"crossref","first-page":"1542","DOI":"10.1200\/JCO.2016.70.1524","article-title":"Pembrolizumab for Platinum- and Cetuximab-Refractory Head and Neck Cancer: Results From a Single-Arm, Phase II Study","volume":"35","author":"Bauml","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"19","key":"10.1016\/j.biopha.2023.114609_bib197","doi-asserted-by":"crossref","first-page":"2125","DOI":"10.1200\/JCO.2016.72.1316","article-title":"Keynote, Phase II Study of the Efficacy and Safety of Pembrolizumab for Relapsed\/Refractory Classic Hodgkin Lymphoma","volume":"35","author":"Chen","year":"2017","journal-title":"J. Clin. Oncol."},{"issue":"20","key":"10.1016\/j.biopha.2023.114609_bib198","doi-asserted-by":"crossref","first-page":"5636","DOI":"10.1158\/1078-0432.CCR-13-0458","article-title":"Anti-PD-1 antibody therapy potently enhances the eradication of established tumors by gene-modified T cells","volume":"19","author":"John","year":"2013","journal-title":"Clin. Cancer Res"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib199","doi-asserted-by":"crossref","DOI":"10.1084\/jem.20200844","article-title":"STING agonist promotes CAR T cell trafficking and persistence in breast cancer","volume":"218","author":"Xu","year":"2021","journal-title":"J. Exp. Med"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib200","doi-asserted-by":"crossref","DOI":"10.1136\/jitc-2021-002500","article-title":"PD-L1 CAR effector cells induce self-amplifying cytotoxic effects against target cells","volume":"10","author":"Bajor","year":"2022","journal-title":"J. Immunother. Cancer"},{"issue":"2","key":"10.1016\/j.biopha.2023.114609_bib201","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1016\/j.soncn.2018.03.006","article-title":"The evolution of radiation therapy in treating cancer","volume":"34","author":"Abshire","year":"2018","journal-title":"Semin Oncol. Nurs."},{"issue":"22","key":"10.1016\/j.biopha.2023.114609_bib202","doi-asserted-by":"crossref","first-page":"1444","DOI":"10.1056\/NEJM199511303332202","article-title":"Effects of radiotherapy and surgery in early breast cancer. An overview of the randomized trials","volume":"333","author":"Early Breast Cancer Trialists' Collaborative","year":"1995","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.biopha.2023.114609_bib203","doi-asserted-by":"crossref","first-page":"1227","DOI":"10.1056\/NEJMoa020989","article-title":"Twenty-year follow-up of a randomized study comparing breast-conserving surgery with radical mastectomy for early breast cancer","volume":"347","author":"Veronesi","year":"2002","journal-title":"N. Engl. J. Med"},{"issue":"16","key":"10.1016\/j.biopha.2023.114609_bib204","doi-asserted-by":"crossref","first-page":"1233","DOI":"10.1056\/NEJMoa022152","article-title":"Twenty-year follow-up of a randomized trial comparing total mastectomy, lumpectomy, and lumpectomy plus irradiation for the treatment of invasive breast cancer","volume":"347","author":"Fisher","year":"2002","journal-title":"N. Engl. J. Med"},{"key":"10.1016\/j.biopha.2023.114609_bib205","doi-asserted-by":"crossref","first-page":"3154","DOI":"10.3389\/fimmu.2018.03154","article-title":"Overcoming Resistance to Combination Radiation-Immunotherapy: A Focus on Contributing Pathways Within the Tumor Microenvironment","volume":"9","author":"Darragh","year":"2018","journal-title":"Front Immunol."},{"key":"10.1016\/j.biopha.2023.114609_bib206","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.addr.2017.01.004","article-title":"Radiotherapy for cancer: present and future","volume":"109","author":"Allen","year":"2017","journal-title":"Adv. Drug Deliv. Rev."},{"issue":"5","key":"10.1016\/j.biopha.2023.114609_bib207","doi-asserted-by":"crossref","first-page":"1259","DOI":"10.1084\/jem.20052494","article-title":"Radiation modulates the peptide repertoire, enhances MHC class I expression, and induces successful antitumor immunotherapy","volume":"203","author":"Reits","year":"2006","journal-title":"J. Exp. Med"},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib208","doi-asserted-by":"crossref","first-page":"3379","DOI":"10.1016\/j.ymthe.2022.07.021","article-title":"Radiation enhances the efficacy of EGFR-targeted CAR-T cells against triple-negative breast cancer by activating NF-kappaB\/Icam1 signaling","volume":"30","author":"Zhou","year":"2022","journal-title":"Mol. Ther."},{"issue":"12","key":"10.1016\/j.biopha.2023.114609_bib209","doi-asserted-by":"crossref","first-page":"1152","DOI":"10.1158\/2326-6066.CIR-17-0189","article-title":"Safety and Efficacy of Intratumoral Injections of Chimeric Antigen Receptor (CAR) T Cells in Metastatic Breast Cancer","volume":"5","author":"Tchou","year":"2017","journal-title":"Cancer Immunol. Res"},{"issue":"1","key":"10.1016\/j.biopha.2023.114609_bib210","doi-asserted-by":"crossref","DOI":"10.1080\/2162402X.2019.1683345","article-title":"GD2-targeted chimeric antigen receptor T cells prevent metastasis formation by elimination of breast cancer stem-like cells","volume":"9","author":"Seitz","year":"2020","journal-title":"Oncoimmunology"},{"issue":"11","key":"10.1016\/j.biopha.2023.114609_bib211","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1016\/0959-8049(96)00185-2","article-title":"Prognostic value of immunohistochemically detected CD44 isoforms CD44v5, CD44v6 and CD44v7-8 in human breast cancer","volume":"32A","author":"Tempfer","year":"1996","journal-title":"Eur. J. Cancer"},{"issue":"7","key":"10.1016\/j.biopha.2023.114609_bib212","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1007\/s00262-020-02516-9","article-title":"Less is more: reducing the number of administered chimeric antigen receptor T cells in a mouse model using a mathematically guided approach","volume":"69","author":"Globerson Levin","year":"2020","journal-title":"Cancer Immunol. Immunother."},{"issue":"9","key":"10.1016\/j.biopha.2023.114609_bib213","doi-asserted-by":"crossref","first-page":"1025","DOI":"10.1038\/ni.3518","article-title":"Targeting natural killer cells in cancer immunotherapy","volume":"17","author":"Guillerey","year":"2016","journal-title":"Nat. Immunol."},{"issue":"8","key":"10.1016\/j.biopha.2023.114609_bib214","doi-asserted-by":"crossref","first-page":"947","DOI":"10.1038\/s41587-020-0462-y","article-title":"Human chimeric antigen receptor macrophages for cancer immunotherapy","volume":"38","author":"Klichinsky","year":"2020","journal-title":"Nat. Biotechnol."},{"issue":"4","key":"10.1016\/j.biopha.2023.114609_bib215","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13040743","article-title":"Adoptive Immunotherapy beyond CAR T-Cells","volume":"13","author":"Titov","year":"2021","journal-title":"Cancers (Basel)"}],"container-title":["Biomedicine & Pharmacotherapy"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223003979?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0753332223003979?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,5,8]],"date-time":"2026-05-08T13:26:01Z","timestamp":1778246761000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0753332223003979"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,6]]},"references-count":215,"alternative-id":["S0753332223003979"],"URL":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114609","relation":{},"ISSN":["0753-3322"],"issn-type":[{"value":"0753-3322","type":"print"}],"subject":[],"published":{"date-parts":[[2023,6]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Advances in chimeric antigen receptor T cells therapy in the treatment of breast cancer","name":"articletitle","label":"Article Title"},{"value":"Biomedicine & Pharmacotherapy","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.biopha.2023.114609","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 The Authors. Published by Elsevier Masson SAS.","name":"copyright","label":"Copyright"}],"article-number":"114609"}}